News

According to the agreement, Sinovac has committed to commercializing the vaccine in China, inclusive of conducting clinical trials, obtaining regulatory approval, and launching the sIPV vaccine. In addition,

Headed by project leader InnaVirVax, the consortium includes Diaxonhit, and two Inserm (French National Institute for Medical Research) units : Southern Paris University (CESP – U1018 – Kremlin

This rise in funding will support ongoing research into preventing cancer, developing new treatments and making existing ones more effective and personalised to the patient. The charity will

Incruse is a once-daily long-acting muscarinic antagonist (LAMA), a type of bronchodilator also known as an anticholinergic. Currently licensed across all EU member states, Incruse is a 55mcg

A full analysis of the trial’s results is scheduled to be completed in the third quarter of 2014, but preliminary data suggests that GM604 shows significant promise for

Nexavar is co-developed by Onyx Pharmaceuticals, an Amgen subsidiary, and Bayer HealthCare Pharmaceuticals, except in Japan where Bayer manages all development. In November 2013, the European Commission (EC)

Trametinib as a single agent has not showed clinical activity in patients who have progressed on a prior BRAF inhibitor therapy. According to the company, before taking trametinib,

Initial focus in the deal for SNBL is to promote Crown Bioscience services to its Japanese clients, in doing so extending SNBL’s service offering. Under the deal, SNBL

The new drug uses Novozymes’ Veltis technology to achieve an extended half-life that means patients are only required to inject their medication once a week. The approval follows